Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PinnacleXon Dec 08, 2022 10:33am
101 Views
Post# 35158921

RE:RE:RE:RE:RE:TH-1902 pause is no reason to blame management

RE:RE:RE:RE:RE:TH-1902 pause is no reason to blame management
SPCEO1 wrote: He did say "we think" but Juniper is correct - Given anyone paying attention knew they should have accumulated enough results by then to know where the trial was headed, it was likely irresponsible to say even that if he was not really pretty certain a good result ultimately would be revealed. But maybe they had seen some good results at that point and he just got one step ahead of himself. Based on the pause, one would have to think that was not the case, but we don't really know what they were looking at in September.

By the way, the same thing can be said about the "a few, several, maybe many" possible indications of the drug working by Christmas comments made in mid August. It is hard to believe Paul was saying these things without an adequate basis for doing so.

juniper88 wrote: Paul shouldn't have said that.  Whether he said "we THINK" or "we have", I haven't heard of any other companies making such a grand statement.  Why did he "THINK" that?  It makes many of us believe that he is seeing at least some efficacy in this open label trial that leads him to think that.  He should have known how his statement would be interpreted by 
 

 


 





That right there us misleading investors and that alone is enough for a lawsuit   RIGHT ON THAT 
<< Previous
Bullboard Posts
Next >>